Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii

Table 1 Peptides, their affinity for HLA-A*1101, and their immunogenicity in humans and for transgenic mice

Peptide Sequences	Protein¹	Affinity² HLA-A*1101	Elicit IFN-γ³ in		Immunogenicity⁴ in mice
			Seropositive human	Seronegative human
KSFKDILPK	SAG1_224-232	54	+	-	+
AMLTAFFLR	GRA6_164-172	3.6	+	-	+
RSFKDLLKK	GRA7_134-142	14	+	-	-
STFWPCLLR	SAG2C_13-21	10	+	-	+
SSAYVFSVK	SPA_250-258	10	+	-	+
AVVSLLRLLK	SPA_89-98	34	+	-	+

¹Peptides derived from these proteins and the position within the proteins
²Binding affinity was performed by MHC binding assay.
³PBMC from four T. gondii-seropositive HLA-A03 supertype persons and four seronegative persons were stimulated with peptides, the T cell that produce IFN-γ were tested by ELISpot assay.
⁴Splenic T cell were isolated from HLA-A*03 supertype(which includes the HLA-A*1101 haplotype) mice 10 to 14 days after peptide immunization and tested for their ability to generate IFN-γ in response to peptide.